0001193125-26-197957
SEC filingAcadia Pharmaceuticals announced the planned retirement of Head of Research and Development Elizabeth H.Z. Thompson, Ph.D., effective year-end 2026, with a transition period and consulting role through key clinical readouts.
The planned retirement of Dr. Thompson, who joined Acadia in 2024, impacts the leadership of the research and development organization critical to advancing the company's pipeline in neurological and rare diseases. Her continued service through the transition and as a consultant until year-end 2026 provides continuity, particularly for the Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis and early Phase 3 execution. CEO Catherine Owen Adams highlighted Dr. Thompson's contributions to strengthening R&D capabilities, pipeline progress, and culture. The company has begun searching for a replacement to maintain momentum in clinical programs, with all trials recruiting and blinded as planned.